Simplified Chinese
scroll down
13
2024-09
I. Methods for Obtaining the Draft for Public Comment 1. Paper Version: The public may review the document at Beijing Minhai Biotechnology Co., Ltd. 2. Electronic Version: Please refer to the attached file. II. Scope of the Public Subject to Comment The scope of this public consultation is limited to citizens, legal entities, and other organizations that are affected by or have a vested interest in the nucleic acid vaccine research and development and pilot‑scale production project. III. Online Link to the Public Comment Form During the period of public notice, if the public has any comments or views regarding the project’s construction or the environmental impact assessment, please complete the Public Comment Form and submit it to the project proponent. Link to download the Public Comment Form: http://www.mee.gov.cn/x
04
2024-09
“My wife and I are both hepatitis B carriers—can we have children?” “I’ve received two vaccine doses but forgot to get the third—what should I do?” “I got the hepatitis B vaccine, but tests show I don’t have antibodies—could there be something wrong with the vaccine I received?”
25
2024-08
I. Project Overview Project Name: Nucleic Acid Vaccine R&D and Pilot-Scale Production Facility Project Nature: Expansion Construction Site: No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing Total Investment: RMB 165.929 million Project Developer: Beijing Minhai Biotechnology Co., Ltd. Project Scope: The project will utilize the fourth floor of Building No. 1—R&D and Pilot-Scale Production—in Minhai Biotechnology’s Internationalized New‑Type Vaccine Industrial Base, along with the reserved workshop spaces on the fifth floor, to establish a pilot‑scale production facility for nucleic acid vaccine bulk solution and another for sub‑packaging. II. Environmental Impact Assessment Agency This time, the commission has been entrusted to Zhonghuan HuiBo (Beijing) International Engineering Technology Consulting Co., Ltd.
24
2024-05
Product Carbon Footprint Accounting Report – Beijing Minhai Biotechnology Co., Ltd.
Product Carbon Footprint Accounting Report – Beijing Minhai Biotechnology Co., Ltd.
11
2024-05
On May 10, 2024, Liu Xueliang, Deputy Secretary of the CPC Daxing District Committee and District Mayor of Beijing, led a delegation to visit and conduct an on-site inspection of Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio), gaining an in-depth understanding of the development status of key enterprises and industry benchmarks in Daxing District. Joining the visit were Wu Hao, Deputy District Mayor; Zhang Bin, Director of the District Government Office; Tang Shengming, Director of the District Bureau of Statistics; Ma Yanzhu, Director of the District Industrial Promotion Center; and Zhang Liqun, Party Secretary and Chairman of the Biomedical Base, among other leaders. Accompanying the delegation were Liu Jiankai, Executive Deputy General Manager, and Li Guanghui, Deputy General Manager, of Minhai Bio. The delegation, led by Liu Xueliang, conducted field visits and…
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%